clinical trial · NCT07463846
A Study to Evaluate ALN-2232 in Participants With Obesity
ObesityALN-2232PlaceboTirzepatide
brief summary
The purpose of this study is to: * evaluate the safety, tolerability, efficacy, pharmacokinetics (PK), and pharmacodynamics (PD) of single ascending doses of ALN-2232 in patients with obesity * evaluate the safety, tolerability, efficacy, PK, and PD of multiple doses of ALN-2232 in patients with obesity * evaluate the safety, tolerability, efficacy, PK, and PD of multiple doses of ALN-2232 co-initiated with tirzepatide in patients with obesity
started
Mar 2, 2026
primary completion
Apr 27, 2027
completion
Mar 2, 2028
last updated
Aug 12, 2026
official title
A Phase 1/2, Randomized, Double-blind, Placebo-controlled, Study of the Safety, Tolerability, Efficacy, Pharmacokinetics, and Pharmacodynamics of ALN-2232 as Monotherapy and Co-initiated With Tirzepatide in Adult Participants With Obesity
sourced from ClinicalTrials.gov · pharmadog mirrors structured fields, not the full protocol